Global Mucinoses Market
Global Mucinoses market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
Mucinoses are an idiopathic and diverse group of skin disorders characterized by deposition of mucin in the dermis. This is mainly caused by to secretion of glycosaminoglycans from the skin. It is one of the rarest conditions in which increased mucin deposition that leads to pustules or nodules on the skin. This condition can arise in the presence of other skin diseases such as dermatitis.
Market Dynamics: Drivers & Restraints
Increasing cases of skin diseases
Skin diseases are an alarming concern among people as the rates are increasing daily due to emerging variants of viruses and other fungal diseases. Due to the increasing number of skin diseases, people are becoming aware of the causes and treatment options. For instance, in March 2023, according to the World Health Organization, skin diseases were 3rd most prevalent cause of illness. It is one of the 10 most common causes of disability.
Most skin diseases cause long-term disability and other complications. According to the British Association of Dermatologists Journal, 2023, studies have reported a skin disorder prevalence of 30–70% in the general population of developing countries.
Side effects of corticosteroids
Mucinoses are idiopathic, management of the disease is only possible which is done using corticosteroids and antibiotics. Cutaneous atrophy is the major adverse effect of the use of corticosteroids on the skin. Oral corticosteroids increase the risk of joint pain and osteoporosis. Blurred vision, fluid retention, and other infection risks are also observed. These factors are expected to hinder the mucinoses market.
Segment Analysis
The global mucinoses market is segmented based on disease type, drug class, route of administration, distribution channel and region.
Follicular mucinosis is Expected to Dominate Market
Follicular mucinosis is developed in patients who are suffering from atopic dermatitis. Dermatitis can progress to mucinoses which becomes severe and cause eczema-like plaques, and follicular papules, with or without alopecia, and pruritus. The use of corticosteroids for treating atopic dermatitis as well as mucinoses is increasing due to their effectiveness in managing the disease. The launch of corticosteroids for treating atopic dermatitis followed by follicular mucinoses is expected to drive the market in the forthcoming period.
For instance, in April 2022, Eli Lilly and Company's Lebrikizumab combined with topical corticosteroids showed significant improvements in disease severity for atopic dermatitis. Also, in June 2023, Intas Pharmaceuticals Ltd launched TOFATAS, a DCGI-approved Tofacitinib Ointment 2% w/w for the treatment of mild to moderate Atopic Dermatitis (AD).
Geographical Analysis
North America is Expected to Dominate the Global Market
North America is expected to hold the largest share of the market due to the prevalence of skin diseases in this region. Skin diseases are common in people in the US, and Canada. A rise in consultations and increased skin disease cases are the factors that are expected to drive the market in the forthcoming period.
According to the National Center for Biotechnology Information, 2023, occupational skin diseases are high among healthcare workers. In the United States, the yearly incidence was 67 cases per 100,000 employees in the last 2 decades, and the incidence of occupational skin diseases was 13%. According to Nature Journal, 2023, in the United States, each person has on average, 1.6 skin diseases per year. It is one of the main reasons for increased dermatologists' consultation.
Market Segmentation
By Disease Type
• Generalized Mucinoses
Reticular erythematous mucinosis
Follicular mucinosis
Cutaneous lupus mucinosis
Others
• Localised Mucinoses
Papular mucinosis
Mucinous naevus
Others
By Drug Class
• Corticosteroids
• Antibiotics
• Others
By Route of Administration
• Intralesional
• Oral
• Topical
• Other
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the mucinoses market include Alencure Biotech, Sanofi SA, GSK plc, Bausch Health, Sandoz International GmbH, Almirall, S.A, Merck & Co., Inc, Pfizer Inc, AstraZeneca, Cipla Limited. among others.
Key Developments
• In June 2022, Pfizer acquired ReViral, a privately held clinical-stage biotech company. The acquisition will demonstrate the organization's approach to progressing and innovating science through in-house competence as well as the partnership with renowned revolutionary companies to deliver innovative significant developments to patient populations afflicted by serious contagious diseases such as mucinoses.
Why Purchase the Report?
• To visualize the global mucinoses market segmentation based on disease type, drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of mucinoses market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global mucinoses market report would provide approximately 65 tables, 68 figures, and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Disease Type
- 3.2. Snippet by Drug Class
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by Distribution Channel
- 3.5. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing cases of skin diseases
- 4.1.1.2. YY
- 4.1.2. Restraints
- 4.1.2.1. Side effects of corticosteroids
- 4.1.2.2. YY
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Pipeline Analysis
- 5.6. Epidemiology
- 5.7. SWOT Analysis
- 5.8. DMI Opinion
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
- 7. By Disease Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 7.1.2. Market Attractiveness Index, By Disease Type
- 7.2. Generalized Mucinoses*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.2.1. Reticular erythematous mucinosis
- 7.2.2.2. Follicular mucinosis
- 7.2.2.3. Cutaneous lupus mucinosis
- 7.2.2.4. Others
- 7.3. Localized Mucinoses
- 7.3.1. Papular mucinosis
- 7.3.2. Mucinous naevus
- 7.3.3. Others
- 8. By Drug Class
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 8.1.2. Market Attractiveness Index, By Drug Class
- 8.2. Corticosteroids*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Antibiotics
- 8.4. Anti-Malarial Drugs
- 8.5. Others
- 9. By Route of Administration
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.1.2. Market Attractiveness Index, By Route of Administration
- 9.2. Oral*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Topical
- 9.4. Intralesional
- 9.5. Other
- 10. By Distribution Channel
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.1.2. Market Attractiveness Index, By Distribution Channel
- 10.2. Hospital Pharmacies*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Retail Pharmacies
- 10.4. Online Pharmacies
- 11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.7.1. U.S.
- 11.2.7.2. Canada
- 11.2.7.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.7.1. Germany
- 11.3.7.2. UK
- 11.3.7.3. France
- 11.3.7.4. Italy
- 11.3.7.5. Spain
- 11.3.7.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.4.7.1. Brazil
- 11.4.7.2. Argentina
- 11.4.7.3. Rest of South America
- 11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.7.1. China
- 11.5.7.2. India
- 11.5.7.3. Japan
- 11.5.7.4. Australia
- 11.5.7.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12. Competitive Landscape
- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis
- 13. Company Profiles
- 13.1. Alencure Biotech *
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
- 13.2. Sanofi SA
- 13.3. GSK plc
- 13.4. Bausch Health
- 13.5. Sandoz International GmbH
- 13.6. Almirall, S.A
- 13.7. Merck & Co., Inc
- 13.8. Pfizer Inc
- 13.9. AstraZeneca
- 13.10. Cipla Limited
- LIST NOT EXHAUSTIVE
- 14. Appendix
- 14.1. About Us and Services
- 14.2. Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook